Look for:

Our offer for

BAUSCH HEALTH COMPANIES INC.


ISIN:
CA0717341071
WKN:
071734107

2024/05/27 22:00:00
Price
8.51 CAD
Difference -2.30% (-0.20)

General attributes

ISINCA0717341071
SymbolBHC
ExchangeToronto Stock Exchange
CurrencyCAD
SectorOther
Security typeStock
Market cap (m)2,148 EUR
BenchmarkS&P/TSX 60 INDEX

Market data

Bid (Bid size)8.49 CAD (1,800)
Ask (Ask size)8.54 CAD (2,000)
Open8.71 CAD
High8.75 CAD
Low8.45 CAD
Close (prev. day)8.71 CAD
VWAP8.53211 CAD
Volume (pcs)141,873
Trading volume1,210,476.04
Number of trades804
Last size100

Futures and Options

Related Futures15
Related Options-

PDF Downloads

Company report: BAUSCH HEALTH COMPANIES INC.PDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

Date Headline Download
2024/04/26 en Global Equity Ratings PDF Download
2024/04/03 en Global Equity Ratings PDF Download
2024/03/13 en Global Equity Ratings PDF Download
2024/02/22 en Global Equity Ratings PDF Download
2024/02/14 en Global Equity Ratings PDF Download


2024/05/27 22:00:00
Price
8.51 CAD
Difference -2.30% (-0.20)

General attributes

ISINCA0717341071
SymbolBHC
ExchangeToronto Stock Exchange
CurrencyCAD
SectorOther
Security typeStock
Market cap (m)2,148 EUR
BenchmarkS&P/TSX 60 INDEX

Market data

Bid (Bid size)8.49 CAD (1,800)
Ask (Ask size)8.54 CAD (2,000)
Open8.71 CAD
High8.75 CAD
Low8.45 CAD
Close (prev. day)8.71 CAD
VWAP8.53211 CAD
Volume (pcs)141,873
Trading volume1,210,476.04
Number of trades804
Last size100

Performance and Risk

6m1Y3Y
Perf (%)-9.28%-23.13%-77.95%
Perf (abs.)-0.87-2.56-30.09
Beta1.361.061.75
Volatility39.4741.1372.35
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)8.72 CAD (283,592)
Ø price 30 days | Ø volume 30 days (pcs.)10.56 CAD (359,365)
Ø price 100 days | Ø volume 100 days (pcs.)11.59 CAD (362,455)
Ø price 250 days | Ø volume 250 days (pcs.)11.00 CAD (355,187)
YTD High | date15.43 CAD (2024/04/03)
YTD Low | date8.45 CAD (2024/05/27)
52 Weeks High | date15.43 CAD (2024/04/03)
52 Weeks Low | date8.45 CAD (2024/05/27)

All listings for BAUSCH HEALTH COMPANIES INC.

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Tradegate2024/05/2722:265.752 EUR0.001
Toronto Stock Exchange2024/05/2722:008.51 CAD1.21804
Stuttgart2024/05/2720:545.712 EUR0.008
SIX Swiss Exchange2019/06/2817:3524.11 CHF0.001
NYSE2024/05/2422:006.36 USD12.9511,198
Munich2024/05/2708:035.942 EUR0.002
Frankfurt2024/05/2709:155.779 EUR0.002
Duesseldorf2024/05/2708:105.777 EUR0.003
Berlin2024/05/2708:035.783 EUR0.003

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=98103&ID_TYPE_IMAGE_LOGO=2

Contact Details

BAUSCH HEALTH COS. INC.
- -
2150 St. Elzéar Boulevard West - H7L 4A8 Laval
Telefon: +1-514-744-6792
Fax: +
E-mail: -

PDF Downloads

Company report: BAUSCH HEALTH COMPANIES INC.PDF Download

Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Members of Management Board

Thomas AppioChairman of Managing Board
Tage RamakrishnaMember of Executive Committee
Cees HeimanMember of Executive Committee
Fernando ZarateMember of Executive Committee
Graham JacksonMember of Executive Committee
Jeff HartnessMember of Executive Committee
Kathleen FitzpatrickMember of Executive Committee
Mirza DautbegovicMember of Executive Committee
Seana CarsonMember of Executive Committee
Tom VadakethMember of Executive Committee

Board of directors

John PaulsonChairman of Supervisory Board
Amy WechslerMember of Supervisory Board
Richard MulliganMember of Supervisory Board
Brett IcahnMember of Supervisory Board
Christian GarciaMember of Supervisory Board
Frank LeeMember of Supervisory Board
Robert PowerMember of Supervisory Board
Sarah KavanaghMember of Supervisory Board
Steven MillerMember of Supervisory Board





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer